What is LightIntegra Technology?
Founded in 2009 and based in Vancouver, BC, LightIntegra Technology is a privately funded entity focused on developing innovative medical diagnostics. The company's primary objective is to minimize platelet refractoriness through its diagnostic solutions. Its flagship product, ThromboLUX, is designed as a routine test for platelet concentrates, aiming to identify which units are best suited for prophylactic and therapeutic applications, thereby enhancing transfusion efficacy.
How much funding has LightIntegra Technology raised?
LightIntegra Technology has raised a total of $4.5M across 2 funding rounds:
Private Equity
$3.5M
Other Financing Round
$1M
Private Equity (2017): $3.5M, investors not publicly disclosed
Other Financing Round (2020): $1M led by Genome British Columbia and Genome Canada
Key Investors in LightIntegra Technology
Genome British Columbia and Genome Canada
Genome Canada is a national organization dedicated to advancing genomics research and innovation, focusing on health, agriculture, and environmental sustainability. They strategically invest in projects that translate research into impactful solutions, supporting the Canadian genomics ecosystem.
What's next for LightIntegra Technology?
With the recent major enterprise-level funding, LightIntegra Technology is poised for significant expansion and further development of its diagnostic technologies. This strategic backing is expected to accelerate the company's efforts in clinical validation, market penetration, and potentially the scaling of its operations to meet the growing demand for advanced platelet management solutions. The company's focus on a critical area of transfusion medicine suggests a trajectory towards becoming a key player in the diagnostics landscape.
See full LightIntegra Technology company page
